179 related articles for article (PubMed ID: 19321281)
41. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
42. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
Hütten M; Lassay L; Sachs B; Deutz P; Mertens R; Baron JM; Merk HF; Ott H
Pediatr Dermatol; 2009; 26(3):349-50. PubMed ID: 19706105
[TBL] [Abstract][Full Text] [Related]
43. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Xie XD; Piao Y; Liu ZZ
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
[No Abstract] [Full Text] [Related]
44. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
Curtit E; Thiery-Vuillemin A; Nguyen T; Heyd B; Pivot X; Di Martino V; Borg C
J Clin Oncol; 2011 Apr; 29(12):e330-2. PubMed ID: 21263091
[No Abstract] [Full Text] [Related]
45. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function.
Kim JE; Ryoo BY; Ryu MH; Chang HM; Suh DJ; Lee HC; Lim YS; Kim KM; Kang YK
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1285-90. PubMed ID: 21445543
[TBL] [Abstract][Full Text] [Related]
46. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
[No Abstract] [Full Text] [Related]
47. Sorafenib-induced destructive thyroiditis.
Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
[No Abstract] [Full Text] [Related]
48. Current problems with systemic treatment of advanced hepatocellular cancer.
He AR; Soe K; El Zouhairi M
Curr Probl Cancer; 2010; 34(2):131-49. PubMed ID: 20417353
[No Abstract] [Full Text] [Related]
49. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
Spira D; Fenchel M; Lauer UM; Claussen CD; Gregor M; Bitzer M; Horger M
Acad Radiol; 2011 Jan; 18(1):89-96. PubMed ID: 20926315
[TBL] [Abstract][Full Text] [Related]
50. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
[No Abstract] [Full Text] [Related]
51. Invasive squamous cell carcinoma and sorafenib in a black patient.
Donaldson MR; Stetson CL; Smith JL
Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
[No Abstract] [Full Text] [Related]
52. Coil extrusion from a gastric varice during sorafenib treatment for hepatocellular carcinoma.
Lucas E; Aubourg A; Bacq Y; Perarnau JM
Dig Liver Dis; 2011 Nov; 43(11):920. PubMed ID: 21763223
[No Abstract] [Full Text] [Related]
53. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Greten TF; Manns MP; Malek N
Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
[TBL] [Abstract][Full Text] [Related]
54. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
van Doorn L; Eskens FA; Visser TJ; van der Lugt A; Mathijssen RH; Peeters RP
Thyroid; 2011 Feb; 21(2):197-202. PubMed ID: 21275767
[TBL] [Abstract][Full Text] [Related]
55. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
[TBL] [Abstract][Full Text] [Related]
56. Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
Verset G; Maréchal R; Bali MA; Devière J; Van Laethem JL
Ann Oncol; 2010 Jun; 21(6):1381-1382. PubMed ID: 20332137
[No Abstract] [Full Text] [Related]
57. [Current advances in molecular targeted therapy of primary hepatocellular carcinoma].
Yu L; Dai Z; Zhou J; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):475-7. PubMed ID: 19567036
[No Abstract] [Full Text] [Related]
58. From a cancer drug fund to value based pricing of drugs.
Duerden M
BMJ; 2010 Aug; 341():c4388. PubMed ID: 20705656
[No Abstract] [Full Text] [Related]
59. Hepatocellular carcinoma treated with sorafenib.
Han G; Zhao Y; Qi X; Fan D
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1347-8; discussion 1348. PubMed ID: 22085376
[No Abstract] [Full Text] [Related]
60. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.
Di Lorenzo G; Imbimbo M; Leopardo D; Marciano R; Federico P; Buonerba C; Salvatore B; Marinelli A; Palmieri G
Int J Immunopathol Pharmacol; 2010; 23(3):951-4. PubMed ID: 20943068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]